IL1R1

Interleukin-1 receptor type 1 UniProt accession P14778

Receptor for IL1A, IL1B and IL1RN (PubMed:2950091, PubMed:37315560). After binding to interleukin-1 associates with the coreceptor IL1RAP to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B, MAPK and other pathways. Signaling involves the recruitment of adapter molecules such as TOLLIP, MYD88, and IRAK1 or IRAK2 via the respective TIR domains of the receptor/coreceptor subunits.

Binds ligands with comparable affinity and binding of antagonist IL1RN prevents association with IL1RAP to form a signaling complex. Involved in IL1B-mediated costimulation of IFNG production from T-helper 1 (Th1) cells (PubMed:10653850)

Source: UniProt

The interleukin-1 receptor complex is a heterodimer of IL1R1 and IL1RAP. Interacts with PIK3R1. Interacts with IL1A (PubMed:2950091)

Source: UniProt
Membrane — Single-pass type I membrane protein, Cell membrane, Secreted
Source: UniProt

Expressed in T-helper cell subsets. Preferentially expressed in T-helper 1 (Th1) cells

Source: UniProt

The TIR domain mediates NAD(+) hydrolase (NADase) activity. Self-association of TIR domains is required for NADase activity

Source: UniProt
  • Chronic recurrent multifocal osteomyelitis 3 (CRMO3)

    An autosomal dominant autoinflammatory bone disease characterized by early-childhood onset of bone pain and arthritis caused by sterile osteomyelitis.

Source: UniProt

Click a pathway to open the interactive Reactome viewer.

Pathway list and interactive viewer: Reactome

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to IL1R1, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 7

NCT ID Condition Brief Title Phase Status
NCT02082899 Allergic Conjunctivitis A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1) PHASE2 COMPLETED
NCT04169022 Acute Myeloid Leukemia AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells NA COMPLETED
NCT01745887 Dry Eye Syndrome A Multi-Center Study Subjects With Dry Eye Syndrome PHASE1 COMPLETED
NCT03265132 Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD) PHASE3 TERMINATED
NCT03002974 Acute Gouty Arthritis A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis PHASE2 COMPLETED
NCT06974877 Cryopyrin-Associated Periodic Syndromes, Amyloidosis Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load PHASE1 RECRUITING
NCT01748578 Dry Eye Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects PHASE1 COMPLETED